CNBC: Actavis swoops in on Allergan for Salix buyout talks

Talk about a love triangle. Actavis ($ACT) made an advance toward Allergan ($AGN) last month, which the latter spurned because it thought it was close to landing Salix ($SLXP). Now, sources tell CNBC that Actavis has swooped in on Salix, with deal talks ongoing. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?